Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia

Am J Hematol. 2019 Oct;94(10):E253-E255. doi: 10.1002/ajh.25567. Epub 2019 Jul 10.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Allografts
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Azacitidine / administration & dosage
  • Bridged Bicyclo Compounds, Heterocyclic / administration & dosage
  • Combined Modality Therapy
  • DNA, Neoplasm / genetics
  • Decitabine / administration & dosage
  • Disease-Free Survival
  • Female
  • Hematopoietic Stem Cell Transplantation
  • High-Throughput Nucleotide Sequencing
  • Humans
  • Kaplan-Meier Estimate
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / genetics
  • Leukemia, Myeloid, Acute / therapy
  • Male
  • Middle Aged
  • Mutation
  • Neoplasm Proteins / genetics
  • Remission Induction
  • Retrospective Studies
  • Risk Assessment
  • Sulfonamides / administration & dosage
  • Treatment Outcome
  • Young Adult

Substances

  • Bridged Bicyclo Compounds, Heterocyclic
  • DNA, Neoplasm
  • Neoplasm Proteins
  • Sulfonamides
  • Decitabine
  • Azacitidine
  • venetoclax